Latham & Watkins represented Frequency Therapeutics and David L. Lucchino, Frequency’s Chief Executive Officer in the case.Plaintiffs claimed the company misled investors about a clinical trial…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
